Strategic Timing of Anti-Retroviral Treatment (START Study)
2016 – Now
The START trial was designed to address the question: In HIV-1 (subsequently referred to as HIV) infected asymptomatic participants with a CD4+ count greater than 500 cells/mm3, is immediate use...
Making Drug Treatment Work: Opportunities and Challenges Towards an Evidence and Rights-Based Approach
2012 – 2014
Compulsory drug detention centers (CDDCs) are common throughout Asia. However, medical treatments for substance use disorders, such as opioid agonist treatment (OAT), are generally unavailable in these settings. In this...
Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D²EFT)
1 January 2017 – Now
First-line antiretroviral regimens are safe, effective and easily administered (one pill taken once daily). Even so, the annual failure rate is around 10-15% of treated patients. Second-line regimens have a...
AmFAR, Foundation for AIDS Research: Treat Asia HIV Observational Database (TAHOD)
2008 – Now
TREAT Asia has pioneered the first database to assess the natural history of HIV disease in treated and untreated patients throughout Asia and the Pacific. In an unprecedented regional collaboration...
AmFAR, Foundation for AIDS Research: TAHOD Tuberculosis Study
The use of highly active antiretroviral therapy (HAART) has led to dramatic reductions in morbidity and mortality in HIV patients. However, tuberculosis (TB) remains a common opportunistic infections and a...
University of New South Wales: The Altair Study
November 2006 – November 2011
Antiretroviral therapy is complicated by drug interactions and contraindications. Novel regimens are needed. This open label study randomly assigned treatment-naive, human immunodeficiency virus (HIV)—infected subjects to receive tenofovir-emtricitabine with efavirenz...
University of New South Wales: The Second-Line Study
March 2010 – March 2013
WHO-recommended second-line antiretroviral therapy (ART) of a pharmacologically enhanced (boosted) protease inhibitor plus nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs) might be compromised by resistance. Results of the 96 week...
University of New South Wales: The ENCORE 1 Study
April 2011 – December 2011
“ENCORE (for Evaluation of Novel Concepts in Optimization of antiRetroviral Efficacy) was a program originally designed to examine the safety and efficacy of lower doses of important antiretroviral drugs (ART)....
WHO: 2nd National Consultation On The Use Of The Antiretroviral Pre-Exposure Prophylaxis (PrEP) To Prevent HIV Acquisition In Malaysia
2018 – 2019
The Second National Consultation on the Use of Antiretroviral Pre-exposure Prophylaxis (PrEP) to Prevent HIV Acquisition was held in Kuala Lumpur, Malaysia, on 4 June 2018. The consultation was convened...